INS and cancer: However, many studies dealt with the topic of cancer risk and medication of DM2 in the last decade predicting a general assumption which reflects our MN results: insulin sensitizer, such as metformin, lower cancer risk while drugs which increase insulin (endogenously or exogenously) increase cancer risk8, 25.